Infant RSV Vaccine Investigational Study

PLEASE NOTE: Enrollment in this study is paused until the 2025 RSV season. To learn more, read below or fill out our form.

RSV (Respiratory Syncytial Virus) is a common seasonal virus. Infants and children are at greater risk of acquiring RSV because of their maturing immune system and lack of prior exposure. Most of the time it causes a mild illness like a cold, but for some children RSV leads to a more severe lung problem.

Unfortunately, 2-3 infants out of every 100 with RSV infections become hospitalized.  In fact, each year in the United States an estimated 58,000 – 80,000 children younger than 5 are hospitalized due to RSV infection.

Compensation of $720 - $1,040 is available for study participants.

Please complete the form below if you would like to learn more from our team about participating, or give us a call at (615) 329-2222 with any questions.

Help Research an RSV Vaccine That Protects Infants and Children

Please share your name and contact information so that we can speak with you about the study, answer any questions, and plan an initial visit.

This field is for validation purposes and should be left unchanged.
Your Name(Required)
How would you describe yourself?*
*Please check all that apply.